oxervate
-
European Clinical Trial for HLB Therapeutics’ RGN-259 Enters Final Analysis StageBig Tech 2025. 3. 27. 14:09
· HLB Therapeutics' European trial for NK treatment RGN-259 is in final analysis. SEOUL, South Korea, March 27, 2025 (IT Times) – HLB Therapeutics has announced a significant milestone in the development of its novel treatment for neurotrophic keratitis (NK), RGN-259. The company revealed today that its European Phase 3 clinical trial, known as SEER-3, has entered its final analysis stage, with ..